TABLE 2.

Therapeutic efficacies of KP-103 and reference drugs in a guinea pig model of tinea unguium^a

Treatment	No. of feet with culture-positive nails/total no. of feet (%)	Log CFU in nails/foot (mean ± SD)	Length (mm) of nails (mean ± SD)
Topical vehicle	10/10 (100)	3.70 ± 0.44	9.47 ± 1.02
1.0% KP-103 solution	10/10 (100)	2.20 ± 0.56b	11.64 ± 1.29c,d
1.0% amorolfine solution	10/10 (100)	3.26 ± 0.54	9.66 ± 1.65
1.0% terbinafine solution	10/10 (100)	3.21 ± 0.47	10.33 ± 1.49
Oral vehicle	10/10 (100)	3.76 ± 0.67	9.41 ± 1.78
Terbinafine (40 mg/kg/day, p.oe)	10/10 (100)	3.80 ± 0.44	9.46 ± 1.69

^aTreatment was started on day 60 postinfection and continued for 30 days.

^bP < 0.01 versus the topical-vehicle-, oral-vehicle-, and oral-terbinafine-treated groups.

^cP < 0.01 versus the topical-vehicle-, oral-vehicle-, topical-amorolfine, and oral-terbinafine-treated groups.

^dP < 0.05 versus the topical-terbinafine-treated group.

^ep.o., orally.